₹589.8
▼ -1.42 -0.24%
06 Aug 2026
NSE Listed · Healthcare
Blue Jet Healthcare Ltd. (BLUEJET)
20-day avg volume: 13.7L shares
- Stock trades at a high P/E of 159.
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹208 Cr | ₹318 Cr | ₹340 Cr | ₹355 Cr | ₹165 Cr | ₹192 Cr | ₹235 Cr | ₹293 Cr |
| EBITDA | ₹77 Cr | ₹133 Cr | ₹147 Cr | ₹124 Cr | ₹73 Cr | ₹54 Cr | ₹88 Cr | ₹107 Cr |
| Net Profit | ₹58 Cr | ₹99 Cr | ₹110 Cr | ₹91 Cr | ₹52 Cr | ₹40 Cr | ₹64 Cr | ₹78 Cr |
| EPS | — | — | — | — | — | — | — | — |
| Metric | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | ₹544 Cr | ₹508 Cr | ₹0 Cr | ₹712 Cr | ₹1,030 Cr | ₹947 Cr |
| EBITDA | ₹201 Cr | ₹195 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net Profit | ₹145 Cr | ₹138 Cr | ₹160 Cr | ₹164 Cr | ₹305 Cr | ₹248 Cr |
| EPS | 1,462.6 | 1,396.27 | — | — | — | — |
| Metric | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Total Assets | ₹375 Cr | ₹536 Cr | ₹862 Cr | ₹1,059 Cr | ₹1,418 Cr | ₹1,641 Cr |
| Total Liabilities | ₹173 Cr | ₹196 Cr | ₹181 Cr | ₹214 Cr | ₹284 Cr | ₹281 Cr |
| Equity | ₹203 Cr | ₹340 Cr | ₹681 Cr | ₹845 Cr | ₹1,133 Cr | ₹1,360 Cr |
| Total Debt | — | — | ₹3 Cr | ₹2 Cr | ₹20 Cr | ₹42 Cr |
| Metric | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | ₹171 Cr | ₹129 Cr | ₹142 Cr | ₹241 Cr | ₹46 Cr | ₹334 Cr |
| Investing | ₹-45 Cr | ₹-51 Cr | ₹-147 Cr | ₹-264 Cr | ₹-35 Cr | ₹-276 Cr |
| Financing | ₹-72 Cr | ₹-27 Cr | ₹-4 Cr | ₹-2 Cr | ₹-19 Cr | ₹-31 Cr |
| Free Cash Flow | ₹171 Cr | ₹129 Cr | ₹82 Cr | ₹67 Cr | ₹-34 Cr | ₹115 Cr |
Healthcare · Biotechnology
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
www.bluejethealthcare.com ↗As of 2026-07-31
Quarterly — figures in %. Latest 12 quarters.
| Period | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 86% | 86% | 86% | 86% | 86% | 86% | 86% | 79.8% | 79.8% | 79.8% | 73.1% | 73.1% |
| FIIs | 2.9% | 2% | 2% | 2.2% | 1.1% | 2.3% | 2% | 1.8% | 1.1% | 0.9% | 0.6% | 0.6% |
| DIIs | 2.8% | 3% | 2.1% | 1.7% | 2% | 1.3% | 0.9% | 3.6% | 4.6% | 4.5% | 9.1% | 9.1% |
| Public | 8.3% | 9% | 9.8% | 10.1% | 10.9% | 10.4% | 11.1% | 14.7% | 14.4% | 14.8% | 17.1% | 17.1% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 55,589 | 48,625 | 42,882 | 41,933 | 43,003 | 54,581 | 70,772 | 80,117 | 80,187 | 79,199 | 78,927 | 78,927 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Akshay Bansarilal Arora | Shareholding of Promoter and Promoter Group | 57.6% | 10.89 Cr |
| Shiven Akshay Arora | Shareholding of Promoter and Promoter Group | 10% | 1.90 Cr |
| Archana Akshay Arora | Shareholding of Promoter and Promoter Group | 5.6% | 1.05 Cr |
| Icici Prudential Pharma Healthcare And Diaganostics (p.h.d) Fund | Public Shareholding | 3.8% | 72,55,905 |
| Shamyak Investment Private Limited | Public Shareholding | 2.9% | 54,34,785 |
| Alka Rakesh Bakshi | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Amit Dhawan | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Anisha Juneja | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Name | Designation | Year |
|---|---|---|
| Akshay Bansarilal Arora | Chairman & Exec. Director | 2025 |
| Shiven Akshay Arora | Executive Director & MD | 2025 |
| Naresh Suiyakant Shah | ED / Head - Marketing | 2025 |
| Popat Kedar | Whole Time Director | 2025 |
| Girish Paman Vanvari | Independent Non Exe. Director | 2025 |
| Divya Momaya | Independent Non Exe. Director | 2025 |
| Prinyanka Yadav | Independent Non Exe. Director | 2025 |
| Preeti Mehta | Independent Non Exe. Director | 2025 |
| Sweta Poddar | Company Sec. & Compli. Officer | 2025 |
| Segment | Revenue | Share |
|---|---|---|
| Business of Manufacturing of Pharma | ₹0 Cr | — |
| Region | Revenue | Share |
|---|---|---|
| Norway | ₹349 Cr | 34% |
| France | ₹434 Cr | 42.4% |
| Domestic Sales | ₹132 Cr | 12.9% |
| Rest of the world # | ₹109 Cr | 10.7% |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹2 | 45 | 35 | 35 |
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-08-03 | Board Meetings | — |
| dividend | 2025-09-19 | ₹1.2 (60%) | Final |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 27 | 0 | 28 |
| 2025 | 0 | 0 | 0 | 19 | 0 | 20 |
| 2025 | 0 | 0 | 0 | 8 | 0 | 8 |
1 disclosure(s)
📍 701,702, 7th Floor Bhumiraj, Costarica Sect. 18 Navi Mumbai, Thane, Maharashtra, 400705
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search